Irhythm Technologies (I25) Price & Analysis

1 Followers

I25 Stock Chart & Stats

€102.00

€2.00(2.19%)

At close: Jul 24 4:00 PM EDT

€102.00

€2.00(2.19%)

Day’s Range― - ―

52-Week Range€87.50 - €179.00

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€3.21B

Enterprise Value€4.05B

Total Cash (Recent Filing)€591.27M

Total Debt (Recent Filing)€727.35M

Price to Earnings (P/E)―

Beta0.51

Next Earnings

Nov 05, 2026

EPS Estimate

0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding32,963,000

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio2.07

Price to Book (P/B)37.18

Price to Sales (P/S)7.60

P/FCF Ratio164.50

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€154.58

Price Target Upside51.55% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

EPS Forecast (FY)-0.18

Revenue Forecast (FY)€792.82M

Bulls Say, Bears Say

Bulls Say

Accelerating Revenue GrowthStrong recent growth and raised full-year guidance indicate expanding utilization of iRhythm’s monitoring platform and effective commercial execution. Sustained top-line momentum can support operating leverage, broaden the customer base, and reinforce the company’s position in ambulatory cardiac monitoring.

VitalConnect Platform ExpansionThe completed VitalConnect acquisition expands iRhythm beyond its existing monitoring offerings and adds capabilities across ambulatory, inpatient and hospital-to-home workflows. A broader product suite can increase addressable market, deepen health-system relationships, and create additional cross-selling opportunities.

Technology-Driven Margin OpportunityAutomating more of the clinical review process could lower service-delivery costs while preserving the value of iRhythm’s data and reporting platform. The expected efficiency gains provide a durable path to higher margins and greater capacity as monitoring volumes grow.

Bears Say

High Financial LeverageThe debt-heavy capital structure reduces financial flexibility and leaves less capacity to absorb operating setbacks or fund additional expansion internally. Higher leverage also creates refinancing and interest-cost exposure, making execution and sustained cash generation more important over the coming quarters.

Profitability And Free Cash Flow Not Yet ConsistentAlthough adjusted results and EBITDA have improved, negative TTM net income and modest, declining free cash flow show that the earnings improvement is not yet fully established on a GAAP or cash basis. Continued investment or working-capital volatility could delay durable self-funded growth.

Outstanding FDA Warning LetterThe unresolved FDA warning letter remains a regulatory overhang that could require further remediation, management attention, or operational changes. Uncertainty around agency closure may complicate product planning and customer confidence until the matter is formally resolved.

Irhythm Technologies News

iRhythm initiated with an Overweight at Piper Sandler

Piper Sandler analyst Adam Maeder initiated coverage of iRhythm (IRTC) with an Overweight rating and $160 price target...

1d ago

IRTC

iRhythm price target lowered to $150 from $168 at Wells Fargo

Wells Fargo lowered the firm’s price target on iRhythm (IRTC) to $150 from $168 and keeps an Overweight...

11d ago

IRTC

iRhythm provides update on cybersecurity incident previously disclosed in June

“iRhythm (IRTC) provided an update regarding the cybersecurity incident previously disclosed in June, 2026. Following completion of the...

15d ago

IRTC

iRhythm Acquires VitalConnect to Expand Cardiac Monitoring

An announcement from Irhythm Technologies ( ($IRTC) ) is now available. On October 5, 2026, iRhythm Holdings completed...

12d ago

IRTC

Irhythm Technologies Clears Antitrust Hurdle for Vital Connect Acquisition

The latest announcement is out from Irhythm Technologies ( ($IRTC) ). On August 5, 2026, iRhythm Holdings, Inc....

25d ago

IRTC

Irhythm: Buy Rating Backed by VitalConnect Acquisition and Compelling 2027 Growth Setup

William Blair analyst Brandon Vazquez has maintained their bullish stance on IRTC stock, giving a Buy rating on...

1M ago

IRTC

iRhythm price target lowered to $168 from $180 at Wells Fargo

Wells Fargo lowered the firm’s price target on iRhythm (IRTC) to $168 from $180 and keeps an Overweight...

2M ago

IRTC

Irhythm Technologies Earnings Call Signals Profitable Growth

Irhythm Technologies (($IRTC)) has held its Q2 earnings call. Read on for the main highlights of the call....

2M ago

IRTC

iRhythm Technologies Announces Audit Committee Leadership Transition

An update from Irhythm Technologies ( ($IRTC) ) is now available. On August 11, 2026, iRhythm Holdings, Inc....

2M ago

IRTC

iRhythm price target raised to $168 from $160 at Truist

Truist raised the firm’s price target on iRhythm (IRTC) to $168 from $160 and keeps a Buy rating...

2M ago

IRTC

iRhythm price target lowered to $192 from $255 at Needham

Needham lowered the firm’s price target on iRhythm (IRTC) to $192 from $255 and keeps a Buy rating...

2M ago

IRTC

iRhythm price target raised to $165 from $150 at Evercore ISI

Evercore ISI analyst Vijay Kumar raised the firm’s price target on iRhythm (IRTC) to $165 from $150 and...

2M ago

IRTC

iRhythm price target raised to $165 from $160 at Baird

Baird raised the firm’s price target on iRhythm (IRTC) to $165 from $160 and keeps an Outperform rating...

2M ago

IRTC

iRhythm price target raised to $196 from $157 at Canaccord

Canaccord raised the firm’s price target on iRhythm (IRTC) to $196 from $157 and keeps a Buy rating...

2M ago

IRTC

I25 FAQ

What was Irhythm Technologies’s price range in the past 12 months?

Irhythm Technologies lowest stock price was €87.50 and its highest was €179.00 in the past 12 months.

What is Irhythm Technologies’s market cap?

Irhythm Technologies’s market cap is €3.21B.

When is Irhythm Technologies’s upcoming earnings report date?

Irhythm Technologies’s upcoming earnings report date is Nov 05, 2026 which is in 19 days.

How were Irhythm Technologies’s earnings last quarter?

Irhythm Technologies released its earnings results on Aug 06, 2026. The company reported -€0.009 earnings per share for the quarter, beating the consensus estimate of -€0.036 by €0.027.

Is Irhythm Technologies overvalued?

According to Wall Street analysts Irhythm Technologies’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Irhythm Technologies pay dividends?

Irhythm Technologies does not currently pay dividends.

What is Irhythm Technologies’s EPS estimate?

Irhythm Technologies’s EPS estimate is 0.01.

How many shares outstanding does Irhythm Technologies have?

Irhythm Technologies has 32,963,000 shares outstanding.

What happened to Irhythm Technologies’s price movement after its last earnings report?

Irhythm Technologies reported an EPS of -€0.009 in its last earnings report, beating expectations of -€0.036. Following the earnings report the stock price went up 5.714%.

Which hedge fund is a major shareholder of Irhythm Technologies?

Currently, no hedge funds are holding shares in DE:I25

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Irhythm Technologies Stock Smart Score

Neutral

Fundamentals

Return on Equity

-8.97%

Trailing 12-Months

Asset Growth

13.42%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Irhythm Technologies

iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.

Irhythm Technologies (I25) Earnings & Revenues

Historic Earnings Reports

I25 Company Deck

I25 Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed strong operational and financial momentum: high‑teens to low‑20% organic revenue growth, record profitability and free cash flow, raised guidance, constructive reimbursement news, and a strategic acquisition (VitalConnect) that expands modality, market opportunity and multivital capabilities. Notable risks discussed include an outstanding FDA warning letter, a recent cybersecurity incident, a $50 million litigation settlement, integration and regulatory review risks related to the VitalConnect acquisition, and the pending clearance of the company’s Zio MCT product. On balance, positive execution, margin expansion, and clear strategic rationale for the acquisition outweigh the manageable regulatory and integration headwinds.View all DE:I25 earnings summaries

I25 Stock 12 Month Forecast

Average Price Target

€154.58

▲(51.55% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"94":"€94","175":"€175","114.25":"€114.3","134.5":"€134.5","154.75":"€154.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":174.7692114,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€174.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":154.58482659545456,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€154.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":133.7519475,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€133.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[94,114.25,134.5,154.75,175],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.5,104.36686241538462,110.23372483076923,116.10058724615385,121.96744966153847,127.83431207692308,133.7011744923077,139.56803690769232,145.43489932307693,151.30176173846155,157.16862415384617,163.03548656923078,168.90234898461537,{"y":174.7692114,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.5,102.81421743041957,107.12843486083916,111.44265229125874,115.75686972167833,120.0710871520979,124.38530458251748,128.69952201293705,133.01373944335666,137.32795687377623,141.6421743041958,145.9563917346154,150.27060916503495,{"y":154.58482659545456,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.5,101.21168826923076,103.92337653846154,106.6350648076923,109.34675307692308,112.05844134615384,114.77012961538462,117.48181788461538,120.19350615384616,122.90519442307692,125.6168826923077,128.32857096153847,131.04025923076924,{"y":133.7519475,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":142,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":155,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.5,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >